GORE CARDIOFORM ASD Occluder ASD27ARecalls & reported problems
W. L. Gore & Associates, Inc. · GORE CARDIOFORM ASD Occluder 27 mm 10Fr · Class 3 · Implant
All models of GORE CARDIOFORM ASD Occluder (5)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00733132636488), received between Dec 17, 2019 and Oct 25, 2022 — classified as 2 injuries.
The most frequently reported specific device problem is “Expulsion” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Expulsion1
- Patient Device Interaction Problem1
Patient problems
- Fever1
- No Code Available1
- Sepsis1
- Thrombosis/Thrombus1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
InjuryOct 25, 2022Patient Device Interaction Problem; Patient Device Interaction Problem
IT WAS REPORTED TO GORE A 27MM GORE® CARDIOFORM ASD OCCLUDER WAS IMPLANTED ON (B)(6) 2022 TO TREAT AN ATRIAL SEPTAL DEFECT. IT WAS REPORTED THE PATIENT PRESENTED TO AN OUTSIDE EMERGENCY DEPARTMENT ON (B)(6) 2022 WITH FEVER/SEPSIS. THE PATIENT THEN PRESENTED TO THE IMPLANTING FACILITY ON (B)(6) 2022 WITH POSITIVE CULTURES AND NEGATIVE ECHOCARDIOGRAM. THE PATIENT WAS ADMITTED. THE FIRST ECHOCARDIOGRAM THAT SHOWED VEGETATION ON THE DEVICE WAS (B)(6) 2022. REPEAT ECHOCARDIOGRAM ON (B)(6) 2022, WHILE ON MULTIPLE ANTIBIOTICS AND ANTICOAGULANTS, SHOWED PROGRESSION OF THE VEGETATION. THE PATIENT HAD PERSISTENT POSITIVE CULTURES (MSSA) AND FEVER. THE DEVICE WAS EXPLANTED ON (B)(6) 2022. DURING THE OPEN CARDIOVASCULAR PROCEDURE, A LARGE VEGETATION COULD BE SEEN ON RIGHT ATRIAL DISC. THERE WAS ALSO A SMALL VEGETATION ON THE LEFT ATRIAL DISC WHEN REMOVED.
Patient problems: Fever; Sepsis; Thrombosis/Thrombus
MAUDE report 15666110 ↗InjuryDec 17, 2019Expulsion; Expulsion
IT WAS REPORTED THE PHYSICIAN IMPLANTED A 27MM GORE® CARDIOFORM ASD OCCLUDER TO CLOSE AN ATRIAL SEPTAL DEFECT ON (B)(6) 2019. THE DEFECT WAS NOT BALLOON SIZED. TRANSTHORACIC ECHOCARDIOGRAPHY ON (B)(6) 2019 SHOWED THE DEVICE HAD EMBOLIZED TO THE LEFT PULMONARY ARTERY. THE EMBOLIZED DEVICE WAS REMOVED BY SNARE IN A TRANSCATHETER PROCEDURE AND A 32MM GORE® CARDIOFORM ASD OCCLUDER WAS IMPLANTED. THE PATIENT IS CURRENTLY STABLE AND DOING WELL.
Patient problems: No Code Available
MAUDE report 9480798 ↗
Other Transcatheter Septal Occluder devices
- Amplatzer™ Septal OccluderAga Medical Corporation · Transcatheter septal occluder294 reports
- Amplatzer™ Septal OccluderAga Medical Corporation · Transcatheter septal occluder1 death213 reports
- Amplatzer™ Talisman™ 9-PFO-3025St. Jude Medical, Inc. · Transcatheter septal occluder1 death193 reports
- GORE CARDIOFORM Septal Occluder GSX0030AW. L. Gore & Associates, Inc. · Transcatheter Septal Occluder1 recall143 reports
- Amplatzer™ 9-ASD-MF-025St. Jude Medical, Inc. · Transcatheter septal occluder1 death183 reports
- Amplatzer™ PFO OccluderSt. Jude Medical, Inc. · Transcatheter septal occluder1 death153 reports
- Amplatzer™ 9-ASD-MF-030St. Jude Medical, Inc. · Transcatheter septal occluder149 reports
- Amplatzer™ Talisman™ 9-PFO-2518St. Jude Medical, Inc. · Transcatheter septal occluder139 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page